Eli Lilly Q1 Earnings Preview Highlights Obesity Portfolio

Analysts remain bullish on Eli Lilly ahead of its Q1 earnings report, with particular focus on the company's obesity drug portfolio and the drug Foundayo. The preview suggests strong performance expectations driven by these key areas.